scholarly journals Beyond Fat Mass: Exploring the Role of Adipokines in Rheumatic Diseases

2011 ◽  
Vol 11 ◽  
pp. 1932-1947 ◽  
Author(s):  
Morena Scotece ◽  
Javier Conde ◽  
Rodolfo Gómez ◽  
Veronica López ◽  
Francisca Lago ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Systemic Lupus Erythematosus ◽  
Adipose Tissue ◽  
Rheumatic Diseases ◽  
White Adipose Tissue ◽  
Immune Cells ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Novel Concept

The cloning of leptin in 1994 by Zhang et al. introduced a novel concept about white adipose tissue (WAT) as a very dynamic organ that releases a plethora of immune and inflammatory mediators, such as adipokines and cytokines, which are involved in multiple diseases. Actually, adipokines exert potent modulatory actions on target tissues involved in rheumatic diseases including cartilage, synovial, bone and immune cells. The goal of this paper is to elucidate the recent findings concerning the involvement of adipokines in rheumatic diseases, such as rheumatoid arthritis (RA), osteoarthritis (OA), and systemic lupus erythematosus (SLE).

scholarly journals Diet in Rheumatoid Arthritis versus Systemic Lupus Erythematosus: Any Differences?

Nutrients ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 772
Author(s):  
Alessia Alunno ◽  
Francesco Carubbi ◽  
Elena Bartoloni ◽  
Davide Grassi ◽  
Claudio Ferri ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Musculoskeletal Diseases ◽  
Normal Subjects ◽  
Experimental Models ◽  
Systemic Lupus ◽  
History Of ◽  
Indirect Action

In recent years, an increasing interest in the influence of diet in rheumatic and musculoskeletal diseases (RMDs) led to the publication of several articles exploring the role of food/nutrients in both the risk of developing these conditions in normal subjects and the natural history of the disease in patients with established RMDs. Diet may be a possible facilitator of RMDs due to both the direct pro-inflammatory properties of some nutrients and the indirect action on insulin resistance, obesity and associated co-morbidities. A consistent body of research has been conducted in rheumatoid arthritis (RA), while studies in systemic lupus erythematosus (SLE) are scarce and have been conducted mainly on experimental models of the disease. This review article aims to outline similarities and differences between RA and SLE based on the existing literature.

Role of Inflammasome Activation in Systemic Lupus Erythematosus: Are Innate Immune Cells Activated?

2020 ◽  
Author(s):  
Rodolfo Perez-Alamino ◽  
Raquel Cuchacovich ◽  
Luis R. Espinoza ◽  
Constance P. Porretta ◽  
Arnold H. Zea
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Immune Cells ◽  
Lupus Erythematosus ◽  
Innate Immune ◽  
Inflammasome Activation ◽  
Innate Immune Cells ◽  
Systemic Lupus

Systemic lupus erythematosus—management

2013 ◽  
pp. 938-947
Author(s):  
Ida Dzifa Dey ◽  
David Isenberg
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Immune Cells ◽  
Lupus Erythematosus ◽  
Immunosuppressive Drugs ◽  
Systemic Lupus ◽  
General Management ◽  
Autoimmune Rheumatic Disease ◽  
The Future

Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease with varied presentation and a disease course characterized by remission and flares. Over the last 50 years the prognosis of SLE has improved considerably. The introductions of corticosteroids and later of cytotoxic drugs, dialysis, and renal transplantation were the major contributors to this improvement. Nevertheless, the treatment and general management of lupus continues to present a challenge. While lupus may, for some patients, represent a relatively mild set of problems, many others require large doses of immunosuppressive drugs, which carry long-term concerns about side effects. New immunotherapeutic drugs, with actions more closely targeted to the immune cells and molecules involved in the pathogenesis of SLE, are being introduced and the future looks promising. The role of early atherosclerosis and cardiovascular disease as a cause of death in patients with SLE is increasingly recognized and will present further challenges in the future.

Expression and Functional Role of HLA-G in Immune Cells from Patients with Systemic Lupus Erythematosus

2010 ◽  
Vol 31 (3) ◽  
pp. 369-378 ◽  
Author(s):  
Adriana Elizabeth Monsiváis-Urenda ◽  
Lourdes Baranda ◽  
Crisol Alvarez-Quiroga ◽  
Carlos Abud-Mendoza ◽  
Roberto González-Amaro
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Immune Cells ◽  
Lupus Erythematosus ◽  
Functional Role ◽  
Systemic Lupus

scholarly journals Pharmacovigilance of Biopharmaceuticals in Rheumatic Diseases, Adverse Events, Evolution, and Perspective: An Overview

Biomedicines ◽  
2020 ◽  
Vol 8 (9) ◽  
pp. 303
Author(s):  
Sandra Rodríguez ◽  
Andrés Muñoz ◽  
Rosa-Helena Bustos ◽  
Diego Jaimes
Keyword(s):  
Rheumatoid Arthritis ◽  
Systemic Lupus Erythematosus ◽  
Adverse Events ◽  
Rheumatic Diseases ◽  
Lupus Erythematosus ◽  
Cell Mediated Immunity ◽  
Systemic Lupus ◽  
Biological Drugs ◽  
Necrosis Factor Alpha ◽  
Post Marketing

Since we have gained an understanding of the immunological pathophysiology of rheumatic diseases such as rheumatoid arthritis and systemic lupus erythematosus, treatment based on biological drugs has become a fundamental axis. These therapies are oriented towards the regulation of cytokines such as tumour necrosis factor-alpha (TNF-α), interleukin (IL)-6, IL-1, and the modulation of cell-mediated immunity (B cells and T cells) by anti CD20 or anti CTAL-4 agents, and can increase the risk of associated infections or adverse events (AE). In this context, the entry of biotherapeutics represented a challenge for pharmacovigilance, risk management and approval by the main global regulatory agencies regarding biosimilars, where efficacy and safety are based on comparability exercises without being an exact copy in terms of molecular structure. The objective of this review is divided into three fundamental aspects: (i) to illustrate the evolution and focus of pharmacovigilance at the biopharmaceutical level, (ii) to describe the different approved recommendations of biopharmaceuticals (biological and biosimilars) and their use in rheumatic diseases (RDs) such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), systemic lupus erythematosus (SLE) and other less frequent RD like cryopyrin-associated autoinflammatory syndromes (CAPS), and (iii) to identify the main AE reported in the post-marketing phase of RD biopharmaceuticals.

scholarly journals EFEITOS DA CINESIOTERAPIA SOBRE A FORÇA DE PREENSÃO PALMAR EM INDIVÍDUOS COM DOENÇAS REUMÁTICAS

2018 ◽  
Vol 7 (1) ◽  
pp. 374-387
Author(s):  
Matheus Santos Gomes Jorge ◽  
Willian Guerra De Lima ◽  
Patrícia Rodigheri Vieira ◽  
Letícia Antoniolli Siiss ◽  
Caroline Zanin ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Systemic Lupus Erythematosus ◽  
Rheumatic Diseases ◽  
Lupus Erythematosus ◽  
Handgrip Strength ◽  
The Body ◽  
Systemic Lupus ◽  
Artrite Reumatoide ◽  
Systemic Manifestations ◽  
The Right

Introdução: as doenças reumáticas apresentam manifestações musculoesqueléticas e sistêmicas que podem acometer quaisquer regiões do corpo. No caso das mãos, uma das manifestações é a diminuição da força de preensão palmar destes indivíduos. Objetivo: verificar os efeitos da cinesioterapia sobre a força de preensão palmar em indivíduos com doenças reumáticas. Material e métodos: estudo longitudinal e intervencionista com 24 indivíduos portadores de doenças reumáticas (osteoartrite, artrite reumatoide, fibromialgia, lúpus eritematoso sistêmico, esclerose sistêmica e dermatopolimiosite), com idade média de 50,23 anos. Os indivíduos realizaram 10 sessões de fisioterapia, baseadas em cinesioterapia, com exercícios globais e funcionais, 02 vezes por semana, com duração média de 50 minutos, de março de 2014 a novembro de 2015, na Clínica de Fisioterapia da Universidade de Passo Fundo, Passo Fundo/RS. As avaliações inicial e final envolveram a coleta de dados e a mensuração da força de preensão palmar, por meio da dinamometria manual. Resultados: observou-se que os indivíduos apresentaram melhora da força de preensão palmar, porém os resultados foram estatisticamente significativos apenas para a mão direita dos indivíduos com osteoartrite, para ambas as mãos dos indivíduos com artrite reumatoide e lúpus eritematoso sistêmico e para a força de preensão palmar geral dos indivíduos. Conclusão: o protocolo fisioterapêutico proposto produziu aumento da força de preensão palmar de indivíduos com doenças reumáticas.Palavras-chave: Força da mão. Doenças reumáticas. Fisioterapia. Reabilitação. Exercício. ABSTRACT: Introduction: rheumatic diseases present musculoskeletal and systemic manifestations that can affect any region of the body. In the case of the hands, one of the manifestations is the decrease of the handgrip strength of these individuals. Aim: to verify the effects of kinesiotherapy on handgrip strength in individuals with rheumatic diseases. Material and methods: longitudinal and interventional study with 24 individuals with rheumatic diseases (osteoarthritis, rheumatoid arthritis, fibromyalgia, systemic lupus erythematosus, systemic sclerosis and dermatopolymyositis), mean age 50.23 years. The individuals performed 10 sessions of physiotherapy, based on kinesiotherapy, with global and functional exercises, 02 times a week, with an mean duration of 50 minutes, from March 2014 to November 2015, at the Physiotherapy Clinic of Passo Fundo University, Passo Fundo/RS. The initial and final evaluations involved data collection and measurement of handgrip strength using manual dynamometry. Results: it was observed that the individuals presented improvement of the handgrip strength, but the results were statistically significant only for the right hand of individuals with osteoarthritis, for both hands of individuals with rheumatoid arthritis and systemic lupus erythematosus and for the handgrip strength of individuals. Conclusion: the proposed physiotherapeutic protocol produced an increase in the handgrip strength of individuals with rheumatic diseases.Keywords: Hand strength. Rheumatic diseases. Physical therapy specialty. Rehabilitation. Exercise.

Sign in / Sign up

Export Citation Format

Share Document